AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.
Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.
AbbVie to record $3.5B impairment charge for Cerevel drug
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year. The drugmaker disclosed in November that two Phase 2 studies of the drug failed to meet their primary endpoint.
AbbVie sees $3.5B impairment charge related to emraclidine
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
Key Takeaways AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics.The biotech company reported in November that the schizophrenia drug,
FierceBiotech2d
AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
2 No-Brainer Dividend Stocks to Buy With $250 in 2025
When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising ...
pharmaphorum3d
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...
Companies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costs
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
AbbVie cuts 2024 profit forecast on acquisition expenses
AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...
Health Care Down on Defensive Bias -- Health Care Roundup
Drugmaker AbbVie warned it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate, a ...
Pharmaceutical Technology12d
Icalcaprant by Cerevel Therapeutics for Bipolar I Disorder: Likelihood of Approval
Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.